<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03052309</url>
  </required_header>
  <id_info>
    <org_study_id>C1604</org_study_id>
    <nct_id>NCT03052309</nct_id>
  </id_info>
  <brief_title>BIOLUX P-III BENELUX All-Comers Registry</brief_title>
  <official_title>BIOTRONIK - A Prospective, International, Multi-centre, Post-market All-comers Registry to Assess the Clinical Performance of the Passeo-18 Lux Paclitaxel Releasing Balloon Catheter in Popliteal Arteries - III BENELUX</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the BIOLUX P-III BENELUX Registry is to further investigate the safety and
      clinical performance of the Passeo-18 Lux Drug Coated Ballon when used in daily clinical
      practice for the treatment of isolated atherosclerotic lesion (vessel narrowing) in popliteal
      arteries
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2017</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from Major Adverse Events (MAE)</measure>
    <time_frame>6 months</time_frame>
    <description>Freedom from Major Adverse Events (MAE): A composite of freedom from device- and procedure-related mortality through 30 days, and freedom from major target limb amputation and clinically driven target lesion revascularization (TLR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from clinically driven target lesion revascularization (cd-TLR)</measure>
    <time_frame>12 months</time_frame>
    <description>Any re-intervention performed for ≥ 50% diameter stenosis (visual estimate) at the target lesion after documentation of recurrent clinical symptoms of the patient.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from clinically-driven target lesion revascularization (cd-TLR)</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from clinically-driven target vessel revascularization (TVR)</measure>
    <time_frame>6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary patency</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>freedom from &gt;50% restenosis in the target lesion as indicated by a duplex ultrasound peak systolic velocity ratio (PSVR) &gt;2.5 or by visual assessment of an angiogram with no clinically driven re-intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from Major Adverse Events (MAE)</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Freedom from Major Adverse Events (MAE): A composite of freedom from device- and procedure-related mortality through 30 days, and freedom from major target limb amputation and clinically driven target lesion revascularization (TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean Ankle Brachial Index (ABI)</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>compared to the pre-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Rutherford classification</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>compared to the pre-procedure Rutherford classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amputation-free survival (AFS)</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>including major, minor and overall AFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>compared to the pre-procedure score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking Impairment Questionnaire</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>compared to the pre-procedure score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>immediately upon index procedure</time_frame>
    <description>Successful delivery, inflation, deflation, and retrieval of the Passeo-18 Lux DCB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success</measure>
    <time_frame>immediately upon index procedure</time_frame>
    <description>Successful completion of the endovascular procedure and immediate morphological success with ≤ 50% residual diameter reduction of the treated lesion as determined by visual estimation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>immediately upon discharge</time_frame>
    <description>Procedural success is technical and device success without the occurrence of any MAE (as defined in the protocol) during the hospital stay</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Passeo-18 Lux DCB</intervention_name>
    <description>The decision to treat the patient with Passeo-18 DCB is at the investigator discretion. The endovascular procedure is performed as per standard of care and device Instructions For Use (IFU)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The BIOLUX P-III BENELUX registry will include subjects from an all-comers patient
        population with all subjects requiring popliteal artery revascularization with the
        Passeo-18 Lux DCB
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years or minimum age as required by local regulations

          -  Subject must be willing to sign a Patient Data Release Form (PDRF) or Patient Informed
             Consent (PIC) where applicable

          -  Lesion(s) in the popliteal arteries suitable for endovascular treatment, treated with
             or scheduled to be treated with the Passeo-18 Lux drug coated balloon.

          -  Isolated popliteal artery lesion: at least 2 cm of healthy segment between lesion(s)
             in the popliteal artery and lesion(s) in distal superficial femoral artery

          -  Inflow free from flow-limiting lesion. Patients with flow-limiting inflow lesions (&gt;
             50% stenosis) can be included if lesion(s) have been treated successfully before or
             during the index procedure, with a maximum residual stenosis of 30% per visual
             assessment

          -  At least one native artery with direct outflow artery to the foot

          -  Rutherford classification 2-5

          -  Patient with bypass surgery in the same limb can be enrolled if there is at least 2 cm
             healthy segment between popliteal artery and anastomosis

        Exclusion Criteria:

          -  Life expectancy ≤ 1 year

          -  Rutherford classification 6

          -  Lesion involving the superficial femoral artery (arterial intersection with the femur
             in an anteroposterior view) or extending in infra-popliteal arteries (origin of the
             anterior tibial artery or tibioperoneal trunk)

          -  Aneurysm at the level of the popliteal artery

          -  Failure to successfully cross the target lesion with a guide wire (successful crossing
             means tip of the guide wire distal to the target lesion in the absence of flow
             limiting dissections or perforations)

          -  Intraprocedural decision not to proceed with the Passeo18 Lux DCB for any reason not
             related to the device (for instance blood flow limiting dissection after
             predilatation)

          -  Subject is currently participating in another investigational drug or device study
             that has not reached its primary endpoint yet

          -  Subject is pregnant or planning to become pregnant during the course of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franck Vermassen</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Gent</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JGAM Blomjous</last_name>
    <role>Principal Investigator</role>
    <affiliation>OLVG Amsterdam</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hélène Kuissu, PharmD</last_name>
    <phone>+41448645368</phone>
    <email>helene.kuissu@biotronik.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ziekenhuis Oost Limburg Genk</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wouter Lansink</last_name>
    </contact>
    <investigator>
      <last_name>Wouter LANSINK</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Gent (UZ Gent)</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank VERMASSEN</last_name>
    </contact>
    <investigator>
      <last_name>Frank VERMASSEN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Groeninge Kortrijk</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annelies Grimonprez</last_name>
    </contact>
    <investigator>
      <last_name>Philip LERUT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Delta Roeselare</name>
      <address>
        <city>Roeselare</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Dujardin</last_name>
    </contact>
    <investigator>
      <last_name>Paul DUJARDIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Portaels</name>
      <address>
        <city>Vilvoorde</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorn ROBIJN</last_name>
    </contact>
    <investigator>
      <last_name>Jorn ROBIJN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitaliers Luxembourg</name>
      <address>
        <city>Luxembourg</city>
        <country>Luxembourg</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Verbeeck</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas VERBEECK</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OLVG</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JGAM BLOMJOUS</last_name>
    </contact>
    <investigator>
      <last_name>JGAM BLOMJOUS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maasstad Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dammis Vroegindeweij</last_name>
    </contact>
    <investigator>
      <last_name>Dammis Vroegindeweij</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum Veldhoven</name>
      <address>
        <city>Veldhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J.W.H KRUIMER</last_name>
    </contact>
    <investigator>
      <last_name>J.W.H KRUIMER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Luxembourg</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2017</study_first_submitted>
  <study_first_submitted_qc>February 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2017</study_first_posted>
  <last_update_submitted>September 26, 2017</last_update_submitted>
  <last_update_submitted_qc>September 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

